Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Wednesday

by · The Cerbat Gem

Sight Sciences (NASDAQ:SGHT – Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Sight Sciences to post earnings of ($0.17) per share and revenue of $20.3540 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

Sight Sciences Stock Performance

Shares of Sight Sciences stock opened at $5.62 on Tuesday. The firm’s fifty day simple moving average is $6.53 and its 200-day simple moving average is $5.76. Sight Sciences has a 12 month low of $2.03 and a 12 month high of $9.24. The stock has a market capitalization of $297.13 million, a price-to-earnings ratio of -6.24 and a beta of 2.43. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.

Analysts Set New Price Targets

SGHT has been the topic of a number of recent research reports. Cantor Fitzgerald set a $8.00 price objective on shares of Sight Sciences in a research note on Monday. Piper Sandler set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. Morgan Stanley boosted their price target on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus upped their price objective on Sight Sciences from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday. Finally, William Blair raised Sight Sciences to a “strong-buy” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.76.

View Our Latest Stock Analysis on Sight Sciences

Insiders Place Their Bets

In other Sight Sciences news, insider Jeremy B. Hayden sold 6,308 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $6.62, for a total transaction of $41,758.96. Following the transaction, the insider owned 267,611 shares in the company, valued at approximately $1,771,584.82. The trade was a 2.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO David Badawi sold 4,836 shares of Sight Sciences stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $6.62, for a total value of $32,014.32. Following the completion of the sale, the chief technology officer owned 1,912,273 shares in the company, valued at approximately $12,659,247.26. This trade represents a 0.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 99,796 shares of company stock worth $719,722 over the last quarter. 28.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in Sight Sciences in the 1st quarter worth about $128,000. Strs Ohio purchased a new position in shares of Sight Sciences during the 1st quarter worth about $158,000. Rhumbline Advisers boosted its position in shares of Sight Sciences by 9.5% in the first quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock worth $120,000 after acquiring an additional 4,319 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Sight Sciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock worth $3,494,000 after acquiring an additional 43,791 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Sight Sciences in the second quarter valued at approximately $67,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

About Sight Sciences

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

Recommended Stories